Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | MMP13 | P45452 | 8/20 | 0.69 |
| ▸ | MMP2 | P08253 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MMP14 | P50281 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6517340 | 0.87 | HRH3 (0.78) | HRH3MMP13MMP2RAB9AKDM4E | |
| SCHEMBL68923 | 0.85 | HRH3 (0.84) | HRH3MMP13MMP2RAB9AKDM4E | |
| SCHEMBL15642660 | 0.85 | HRH3 (0.74) | HRH3MMP13MMP2RAB9AKDM4E | |
| SCHEMBL6522481 | 0.85 | HRH3 (0.74) | HRH3MMP13MMP2RAB9AKDM4E | |
| SCHEMBL3242684 | 0.84 | HRH3 (0.72) | HRH3MMP13MMP2RAB9AKDM4E | |
| SCHEMBL1306748 | 0.83 | HRH3 (1.00) | HRH3MMP13MMP2RAB9AKDM4E | |
| SCHEMBL2342439 | 0.83 | HRH3 (0.80) | HRH3MMP13MMP2RAB9AKDM4E | |
| SCHEMBL3633428 | 0.83 | PIN1 (0.55) | HRH3MMP13MMP2KDM4EALDH1A1 | |
| SCHEMBL6517054 | 0.82 | MMP13 (1.00) | HRH3MMP13MMP2RAB9AKDM4E | |
| SCHEMBL6512101 | 0.81 | HRH3 (0.76) | HRH3MMP13MMP2RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278089-B2 | Method of treating HCV infection with a small molecule CHK2 inhibitor | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-08 | — | — | US | disclosed |
| US-20140294767-A1 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | PROVID PHARMACEUTICALS, INC. | 2014-10-02 | — | — | US | disclosed |
| EP-2770993-A2 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8765802-B2 | Kinase inhibitors, compositions thereof, and methods of use therewith | PROVID PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2155675-B1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS INC (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2013063462-A2 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-05-02 | — | — | WO | disclosed |
| EP-2155675-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | Provid Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. | 2009-01-15 | — | — | US | disclosed |
| WO-2008156573-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | PROVID PHARMACEUTICALS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140294767-A1 | METHOD OF TREATING HCV INFECTION WITH A SMALL MOLECULE CHK2 INHIBITOR | CHEK2, CHEK1, CDK2 | HRH3 2777/4885MMP13 4743/4885MMP2 4386/4885 |
| US-20090018141-A1 | KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH | CHEK2, ATM, CHEK1 | HRH3 2502/4885MMP13 4574/4885MMP2 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.